Calydon Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $17.7M
Latest Deal Amount

Calydon General Information

Description

Developer of therapeutic products for cancer. The company is focused on the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies.

Contact Information

Website
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Acquirer
Primary Office
  • 1331 Hillview Drive
  • Menlo Park, CA 94025
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Calydon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 05-Sep-2001 $17.7M 000.00 000.00 Completed Clinical Trials - Phase 2
2. Early Stage VC 11-Dec-1997 000.00 000.00 Completed Product Development
1. Early Stage VC $3.8M $3.8M Completed
To view Calydon’s complete valuation and funding history, request access »

Calydon Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AmBex Venture Partners Venture Capital Minority 000 0000 000000 0
Genesis Merchant Partners Lender/Debt Provider Minority 000 0000 000000 0
Kevin D'Silva Angel (individual) Minority 000 0000 000000 0
Perseus (Bethesda) PE/Buyout Minority 000 0000 000000 0
Sequoia Capital Venture Capital Minority 000 0000 000000 0
To view Calydon’s complete investors history, request access »